Miriam Jacobs, MD| Hematology Oncology | MedStar Health

Miriam Jacobs, MD
Provider is directly employed by MedStar Health

Specialties: Hematology Oncology

Languages: English


About me

Miriam Jacobs, MD, is board-certified and fellowship-trained in medical oncology at MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital. As a specialist in early and advanced breast cancers, Dr. Jacobs provides chemotherapy, hormone therapy, immunotherapy, precision medicine, and clinical trials. She is also a member of the American Association of Cancer Research, the American Society of Hematology, and the American Society of Clinical Oncology. 

Dr. Jacobs’ approach to care focuses on providing individualized and holistic treatments. She begins by talking with patients to learn about their medical histories and health goals. She then collaborates with an experienced team of radiation oncologists and surgeons to develop comprehensive and tailored wellness plans. She also educates patients about natural, traditional, and state-of-the-art cancer treatments.

Dr. Jacobs is dedicated to advancing the field of precision medicine – an innovative form of care that uses people’s own cells to develop highly personalized prevention, diagnosis, and treatment options. She is particularly interested in providing hormone receptor-positive, CAR T-cell, and CAR NK-cell therapies to improve the health of breast cancer survivors. Referring physicians should know that she is available to give second opinions and discuss clinical trial opportunities.

Philosophy of care

“Research creates endless possibilities to discover new methods of treating complex diseases or enhancing people’s lives. As a clinical researcher, I’m passionate about contributing to the collection of knowledge that can lead to immediate medical solutions or future health innovations. I’m also grateful to clinical trial participants who are true healthcare pioneers and heroes.”

About the MedStar Georgetown Cancer Institute

MedStar Georgetown is part of the MedStar Georgetown Cancer Institute, which combines medical expertise, the latest therapies, and research across MedStar Health. Our research engine, Georgetown University’s Lombardi Comprehensive Cancer Center, is the only National Cancer Institute-designated comprehensive cancer center in the Washington, D.C., region. This partnership means we provide access to cutting-edge clinical trials and the latest breakthroughs in cancer care.

Clinical areas of focus

  • Breast Cancer
  • HER2 Positive Breast Cancer
  • Hormone Receptor Positive Breast Cancer
  • Metastatic Breast Cancer
  • Triple Negative Breast Cancer
Show More

Conditions and procedures

Conditions I treat

  • Abnormal Mammogram
  • Adolescent And Young Adult Cancer (AYA)
  • Atm Mutation
  • Atypical Ductal Hyperplasia
  • Atypical Lobular Hyperplasia
  • Axillary Lymphadenopathy
  • Breast Cancer
  • HER2 Positive Breast Cancer
  • Hormone Receptor Positive Breast Cancer
  • Metastatic Breast Cancer
  • Triple Negative Breast Cancer
Show All Show Less

Procedures I perform

  • Adjuvant Chemotherapy
  • Adjuvant Chemotherapy
  • Adjuvant Radiation Therapy
  • Areola Sparing Mastectomy
  • Aromatase Inhibitor
Show All button Press enter to expand Show Less


Board Certification: American Board of Internal Medicine, Internal Medicine

Board Certification: American Board of Internal Medicine, Medical Oncology

Fellowship Program: Washington University/Barnes Jewish Hospital (2021)

Residency Program: University of California San Diego (2015)

Medical School: Ben Gurion University (2012)


  • Abstract Achievement Award, American Society of Hematology (December 2019) Dean’s Scholar Award, Washington University School of Medicine (July 2022-Present)

News and publications

A Noncompetitive Inhibitor of Serotonin Transport, Acts by Stabilizing the Cytoplasmic-Facing Form of the Transporter, Journal of Biological Chemistry, August 2007

A Conformational Mechanism for Neurotransmitter Transporters, Proceedings of the National Academy of Sciences, July 2008

A Conserved Asparagine Residue in TM1 of the Serotonin Transporter Dictates Chloride-Coupled Neurotransmitter Transport, Journal of Biological Chemistry, July 2011

Use of Low Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small Cell Lung Cancer, JCO Precision Oncology, 2018

Genomic Landscape of Appendiceal Neoplasms, JCO Precision Oncology, 2018

The Use of Ruxolitinib for Acute Graft-Versus Host Disease Developing After Solid Organ Transplantation, American Journal of Transplantation, February 2020

Outcomes of Patients with Large B-Cell Lymphoma Progressing After Axicabtagene Cilolecuel Therapy, Blood, April 1, 2021

Memory-Like Differentiation Enhances NK Cell Response to Melanoma, Clinical Cancer Research, August 3, 2021

CD7 Deleted Hematopoietic Stem Cells Can Restore Immunity After CAR T-Cell Therapy, Journal of Clinical Investigation Insights, August 23, 2021

Systemic IL-15 Promotes Allogeneic Cell Rejection in Patients Treated with Natural Killer Cell Adoptive Therapy, Blood, February 24, 2022

Hematopoietic Cell Transplantation Donor-Derived Memory-Like NK Cells Functionally Persist After Transfer Into Patients with Leukemia, Science Translational Medicine, February 23, 2022

Severity of Cytokine Release Syndrome Influences Outcomes After Axicabtagene Ciloleucel for Large B Cell Lymphoma, Clinical Lymphoma Myeloma and Leukemia, October 22, 2022

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice, Journal of Clinical Oncology, December 2022